Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 + talazoparib in TNBC (China cohort C)
CTR20222240Phase 2Completed
- Sponsor
- Zenith Epigenetics
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ZEN3694 and talazoparib in breast cancer, sponsored by Zenith Epigenetics. Primary endpoint: Objective response rate (ORR) by investigator and independent review (cohort A). Started Sep 2022; status: completed.
02
Drugs
ZEN3694talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20222240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222240.